| 10.8 0.28 (2.66%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.01 |
1-year : | 15.19 |
| Resists | First : | 11.14 |
Second : | 13.01 |
| Pivot price | 9.93 |
|||
| Supports | First : | 9.38 |
Second : | 8.3 |
| MAs | MA(5) : | 10.31 |
MA(20) : | 9.68 |
| MA(100) : | 7.59 |
MA(250) : | 11.04  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 81.8 |
D(3) : | 77.6 |
| RSI | RSI(14): 61.7 |
|||
| 52-week | High : | 25.28 | Low : | 3.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FTRE ] has closed below upper band by 6.3%. Bollinger Bands are 15.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.53 - 10.61 | 10.61 - 10.67 |
| Low: | 9.97 - 10.05 | 10.05 - 10.11 |
| Close: | 10.42 - 10.54 | 10.54 - 10.63 |
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Mon, 20 Oct 2025
Why Fortrea (FTRE) Stock Is Trading Up Today - The Globe and Mail
Mon, 20 Oct 2025
Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt - The Globe and Mail
Mon, 20 Oct 2025
$75.74M Tender Offer: Fortrea to Purchase 7.5% Senior Secured Notes Due 2030; Expires Nov 18, 2025 - Stock Titan
Fri, 17 Oct 2025
Fortrea Holdings Inc. (FTRE) Stock Analysis: Can This Biotech Innovator Turn Challenges Into Opportunities? - DirectorsTalk Interviews
Wed, 15 Oct 2025
Nov. 5 Q3 Results: Fortrea to Report Third-Quarter 2025 and Host 8:00 AM ET Call; Replay - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 91 (M) |
| Shares Float | 84 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 111.3 (%) |
| Shares Short | 10,420 (K) |
| Shares Short P.Month | 10,510 (K) |
| EPS | -11.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.48 |
| Profit Margin | -37.6 % |
| Operating Margin | -1.6 % |
| Return on Assets (ttm) | -1.5 % |
| Return on Equity (ttm) | -100.5 % |
| Qtrly Rev. Growth | 7.1 % |
| Gross Profit (p.s.) | 5.93 |
| Sales Per Share | 30.06 |
| EBITDA (p.s.) | 0.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -88 (M) |
| Levered Free Cash Flow | 30 (M) |
| PE Ratio | -0.95 |
| PEG Ratio | 0 |
| Price to Book value | 1.66 |
| Price to Sales | 0.35 |
| Price to Cash Flow | -11.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|